Human immunodeficiency virus impairs reverse cholesterol transport from macrophages

PLoS Biology

Volumn 4, Issue 11, 2006, Pages 1970-1983

  Mujawar, Zahedi ^a   Rose, Honor ^b   Morrow, Matthew P ^a   Pushkarsky, Tatiana ^a   Dubrovsky, Larisa ^a   Mukhamedova, Nigora ^b   Fu, Ying ^b   Dart, Anthony ^b   Orenstein, Jan M ^a   Bobryshev, Yuri V ^c   Bukrinsky, Michael ^a   Sviridov, Dmitri ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; NEF PROTEIN; ABC TRANSPORTER; CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPID METABOLISM; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN TRANSPORT; VIRUS REPLICATION; ANIMAL; CELL LINE; DOWN REGULATION; FOAM CELL; GENETICS; HELA CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MOLECULAR GENETICS; PATHOGENICITY; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; CHOLESTEROL; DOWN-REGULATION; FOAM CELLS; GENE PRODUCTS, NEF; HELA CELLS; HIV; HIV INFECTIONS; HUMANS; MACROPHAGES; MICE; MOLECULAR SEQUENCE DATA;

EID: 33751062798     PISSN: 15457885     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.0040365     Document Type: Article

References (75)

1. Maziere JC, Landureau JC, Giral P, Auclair M, Fall L, et al. (1994) Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother 48: 63-67.
2. Ono A, Freed EO (2001) Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A 98: 13925-13930.
3. Campbell SM, Crowe SM, Mak J (2002) Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS 16: 2253-2261.
4. Guyader M, Kiyokawa E, Abrami L, Turelli P, Trono D (2002) Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol 76: 10356-10364.
5. Zheng YH, Plemenitas A, Fielding CJ, Peterlin BM (2003) Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci U S A 100: 8460-8465.
6. Barbaro G (2002) Cardiovascular manifestations of HIV infection. Circulation 106: 1420-1425.
7. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, et al. (2005) Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naive cohort. HIV Med 6: 114-121.
8. Escaut L, Monsuez JJ, Chironi G, Merad M, Teicher E, et al. (2003) Coronary artery disease in HIV infected patients. Intensive Care Med 29: 969-973.
9. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, et al. (2004) Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109: 1603-1608.
10. Blum A, Hadas V, Burke M, Yust I, Kessler A (2005) Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction. Clin Cardiol 28: 149-153.
11. Lusis AJ (2000) Atherosclerosis. Nature 407: 233-241.
12. Blessing E, Kuo CC, Lin TM, Campbell LA, Bea F, et al. (2002) Foam cell formation inhibits growth of Chlamydia pneumoniae but does not attenuate Chlamydia pneumoniae-induced secretion of proinflammatory cytokines. Circulation 105: 1976-1982.
13. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, et al. (1992) Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74: 1045-1052.
14. Crook MA, Mir N (1999) Abnormal lipids and the acquired immunodeficiency syndrome: Is there a problem and what should we do about it? Int J STD AIDS 10: 353-356.
15. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, et al. (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7: 1327-1331.
16. Nguyen AT, Gagnon A, Angel JB, Sorisky A (2000) Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS 14: 2467-2473.
17. Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, et al. (2003) HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 111: 389-397.
18. Klein D, Hurley LB, Quesenberry CP Jr., Sidney S (2002) Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 30: 471-477.
19. Charakida M, Donald AE, Green H, Storry C, Clapson M, et al. (2005) Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 112: 103-109.
20. David MH, Hornung R, Fichtenbaum CJ (2002) Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 34: 98-102.
21. Neumann T, Woiwoid T, Neumann A, Miller M, Ross B, et al. (2003) Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: part I. Differences due to the acquisition of HIV-infection. Eur J Med Res 8: 229-235.
22. Varriale P, Saravi G, Hernandez E, Carbon F (2004) Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J 147: 55-59.
23. Jessup W, Gelissen IC, Gaus K, Kritharides L (2006) Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 17: 247-257.
24. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, et al. (2003) Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 12: 805-816.
25. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR (2003) Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: Differential role of LXR. J Lipid Res 44: 1728-1736.
26. Feng B, Tabas I (2002) ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages. Mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity. J Biol Chem 277: 43271-43280.
27. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, et al. (2002) Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 22: 630-637.
28. Oram JF (2000) Tangier disease and ABCA1. Biochim Biophys Acta 1529: 321-330.
29. Attie AD, Kastelein JP, Hayden MR (2001) Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res 42: 1717-1726.
30. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, et al. (1988) Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 167: 1428-1441.
31. Aiken C (1997) Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 71: 5871-5877.
32. Oram JF, Lawn RM (2001) ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 42: 1173-1179.
33. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, et al. (2005) ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 1: 121-131.
34. Oram JF (2003) HDL apolipoproteins and ABCA1: Partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol 23: 720-727.
35. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, et al. (2001) Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun 280: 818-823.
36. Neufeld EB, Remaley AT, Demosky SJ, Stonik JA, Cooney AM, et al. (2001) Cellular localization and trafficking of the human ABCA1 transporter. J Biol Chem 276: 27584-27590.
37. Albrecht C, Soumian S, Amey JS, Sardini A, Higgins CF, et al. (2004) ABCA1 expression in carotid atherosclerotic plaques. Stroke 35: 2801-2806.
38. Neufeld EB, Stonik JA, Demosky SJ Jr., Knapper CL, Combs CA, et al. (2004) The ABCA1 transporter modulates late endocytic trafficking: Insights from the correction of the genetic defect in Tangier disease. J Biol Chem 279: 15571-15578.
39. Chen W, Wang N, Tall AR (2005) A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes. J Biol Chem 280: 29277-29281.
40. Wang N, Silver DL, Costet P, Tall AR (2000) Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 275: 33053-33058.
41. Oram JF, Lawn RM, Garvin MR, Wade DP (2000) ABCA1 Is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 275: 34508-34511.
42. Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, et al. (2004) Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J Biol Chem 279: 7384-7394.
43. Le Goff W, Peng DQ, Settle M, Brubaker G, Morton RE, et al. (2004) Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I. Arterioscler Thromb Vasc Biol 24: 2155-2161.
44. Coleman SH, Madrid R, Van Damme N, Mitchell RS, Bouchet J, et al. (2006) Modulation of cellular protein trafficking by human immunodeficiency virus type 1 Nef: Role of the acidic residue in the ExxxLL motif. J Virol 80: 1837-1849.
45. Garcia JV, Miller AD (1991) Serine phosphorylation-independent down-regulation of cell-surface CD4 by nef. Nature 350: 508-511.
46. Kasper MR, Roeth JF, Williams M, Filzen TM, Fleis RI, et al. (2005) HIV-1 Nef disrupts antigen presentation early in the secretory pathway. J Biol Chem 280: 12840-12848.
47. Sparrow CP, Baffic J, Lam MH, Lund EG, Adams AD, et al. (2002) A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem 277: 10021-10027.
48. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE (2001) Lipid rafts and HIV pathogenesis: Host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 17: 1009-1019.
49. Chen W, Sun Y, Welch C, Gorelik A, Leventhal AR, et al. (2001) Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes. J Biol Chem 276: 43564-43569.
50. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM (1996) Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2: 338-342.
51. Swigut T, Shohdy N, Skowronski J (2001) Mechanism for down-regulation of CD28 by Nef. EMBO J 20: 1593-1604.
52. Sol-Foulon N, Moris A, Nobile C, Boccaccio C, Engering A, et al. (2002) HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 16: 145-155.
53. Arora VK, Fredericksen BL, Garcia JV (2002) Nef: Agent of cell subversion. Microbes Infect 4: 189-199.
54. Caldwell GA, Wang SH, Naider F, Becker JM (1994) Consequences of altered isoprenylation targets on a-factor export and bioactivity. Proc Natl Acad Sci USA 91: 1275-1279.
55. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, et al. (2003) Impact of HIV infection and HAART on serum lipids in men. JAMA 289: 2978-82.
56. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, et al. (2004) Thematic review series: The pathogenesis of atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host. J Lipid Res 45: 1169-1196.
57. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, et al. (1993) Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 94: 515-519.
58. Gianturco SH, Ramprasad MP, Song R, Li R, Brown ML, et al. (1998) Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocytemacrophage receptor. Arterioscler Thromb Vasc Biol 18: 968-976.
59. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, et al. (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104: 257-262.
60. Badiou S, Merle DB, Dupuy AM, Baillat V, Cristol JP, et al. (2003) Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: An index of atherogenicity? Atherosclerosis 168: 107-113.
61. Chait A, Brazg RL, Tribble DL, Krauss RM (1993) Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94: 350-356.
62. St Pierre AC, Ruel IL, Cantin B, Dagenais GR, Bernard PM, et al. (2001) Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 104: 2295-2299.
63. Aquaro S, Bagnarelli P, Guenci T, De Luca A, Clementi M, et al. (2002) Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol 68: 479-488.
64. Leinonen M, Saikku P (2002) Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2: 11-17.
65. Morre SA, Stooker W, Lagrand WK, van den Brule AJ, Niessen HW (2000) Microorganisms in the aetiology of atherosclerosis. J Clin Pathol 53: 647-654.
66. Streblow DN, Orloff SL, Nelson JA (2001) Do pathogens accelerate atherosclerosis? J Nutr 131: 2798S-2804S.
67. Schmidtmayerova H, Nuovo GJ, Bukrinsky M (1997) Cell proliferation is not required for productive HIV-1 infection of macrophages. Virology 232: 379-84.
68. Chang LJ, Urlacher V, Iwakuma T, Cui Y, Zucali J (1999) Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther 6: 715-728.
69. Escher G, Hoang A, Georges S, Tchoua U, El Osta A, et al. (2005) Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages. J Lipid Res 46: 356-365.
70. Sviridov D, Pyle LE, Fidge N (1996) Efflux of cellular cholesterol and phospholipid to apolipoprotein A-I mutants. J Biol Chem 271: 33277-33283.
71. Sviridov D, Hoang A, Huang W, Sasaki J (2002) Structure-function studies of apoA-I variants: Site-directed mutagenesis and natural mutations. J Lipid Res 43: 1283-1292.
72. Fu Y, Hoang A, Escher G, Parton RG, Krozowski Z, et al. (2004) Expression of caveolin-1 enhances cholesterol efflux in hepatic cells. J Biol Chem 279: 14140-14146.
73. Simm M, Shahabuddin M, Chao W, Allan JS, Volsky DJ (1995) Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol 69: 4582-4586.
74. Bobryshev YV, Lord RS (1998) Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immuneinflammatory reactions. Cardiovasc Res 37: 799-810.
75. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, et al. (1994) HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 241: 651-662.